Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    X-Cite

    Sildenafil Citrate
    Tablet 50 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Sildenafil is indicated for the treatment of erectile dysfunction.
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Sildenafil is a selective inhibitor of cyclic Guanosine Monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) used for treatment of erectile dysfunction. Danafil (Sildenafil) enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum that results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
    DosageView
    The recommended dose of Sildenafil is 50 mg taken approximately 1 hour before sexual activity. However, Sildenafil may be taken anywhere from half an hour to 4 hours before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum 100 mg or decreased to 25 mg. The maximum recommended dosing frequency is once per day.
    AdministrationView
    Sildenafil may takes longer time to work if you take it with a heavy meal.
    Side effectsView
    The adverse effects treated with Sildenafil are headache, flushing, dyspepsia, nasal congestion, urinary tract infection, abnormal vision, diarrhea, dizziness and rash.
    ContraindicationsView
    Sildenafil is contraindicated in patient with hypersensitivity to any component of this medication. Sildenafil potentiates the hypotensive effects of nitrates, so it is contraindicated in patients who are using organic nitrates, either regularly or intermittently.
    PrecautionsView
    Caution should be exercised if patients have any allergies to any other medicines or any other substances such as foods, preservatives or dyes, heart or blood vessel problems, sudden loss of eyesight in one or both eyes. Caution should be taken if patients have any of the following medical conditions such as diabetes, kidney or liver problems, leukaemia, multiple myeloma, any disease or deformity of penis, any bleeding disorder such as haemophilia, stomach ulcer, sickle cell anaemia, color vision problems, sudden decrease or loss of hearing or receiving any other treatment for impotence.
    InteractionsView
    Concomitant use of Sildenafil with organic nitrates for angina may cause hypotension. Cimetidine, a medicine used to treat gastric ulcers, some antibiotics including Erythromycin and Rifampicin, some protease inhibitors such as Ritonavir and Saquinavir for the treatment of HIV infection may increase the plasma concentration of Sildenafil. Some medicines used to treat fungal infections including Ketoconazole and Itraconazole may reduce the clearance of Sildenafil.
    Pregnancy & lactationView
    Pregnancy category B. There are no adequate and well-controlled studies of Sildenafil in pregnant women. Sildenafil is not indicated for use by women. In animal study shows that Sildenafil has no evidence of teratogenicity or embryotoxicity.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    X-Cold

    Ambroxol Hydrochloride
    Syrup 15 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    X-Cold

    Ambroxol Hydrochloride
    Pediatric Drops 6 mg/ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    X-Din

    Fexofenadine Hydrochloride
    Oral Suspension 30 mg/5 ml Allopathic Non-sedating antihistamines

    Indications

    Urticaria

    Indication detailsView
    Fexofenadine Hydrochloride is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children. It is also indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria.
    Therapeutic classView
    Non-sedating antihistamines
    PharmacologyView
    Fexofenadine Hydrochloride is an antihistamine with selective peripheral H1-receptor antagonist activity. It is rapidly absorbed after oral administration and peak plasma concentration is reached in 2-3 hours. It does not appear to cross the blood brain barrier.
    DosageView
    Seasonal Allergic Rhinitis-

    Adults and children 12 years and older:
    • Tablet: 60 mg twice daily or 120 mg once daily or 180 mg once daily
    • In case of impaired renal function: 60 mg once daily
    Children from 6 to 11 years:
    • Tablet: 30 mg twice daily or 60 mg once daily
    • In case of impaired renal function: 30 mg once daily
    Children from 2 to 11 years
    • Suspension: 30 mg or 5 ml twice daily
    • In case of impaired renal function: 30 mg or 5 ml once daily


    Chronic Idiopathic Urticaria-

    Adults and children 12 years and older:
    • Tablet: 60 mg twice daily or 120 mg once daily or 180 mg once daily 
    • In case of impaired renal function: 60 mg once daily
    Children from 6 to 11 years:
    • Tablet: 30 mg twice daily or 60 mg once daily
    • In case of impaired renal function: 30 mg once daily
    Children from 6 months to less than 2 years:
    • Suspension: 15 mg or 2.5 ml (1/2 tsp) twice daily
    • In case of impaired renal function: 15 mg or 2.5 ml (1/2 tsp) once daily
    Children from 2 to 11 years:
    • Suspension: 30 mg or 5 ml (1 tsp) twice daily
    • In case of impaired renal function: 30 mg or 5 ml (1 tsp) once daily

    Side effectsView
    Common side effects are headache, fatigue, drowsiness, nausea, dry mouth and gastrointestinal disturbances.
    ContraindicationsView
    Contraindicated in patients with known hypersensitivity to Fexofenadine Hydrochloride or any of its ingredients.
    PrecautionsView
    Caution should be exercised in elderly patient and patient with decreased renal function.
    InteractionsView
    Plasma concentration of Fexofenadine Hydrochloride have been increased when given with erythromycin or ketoconazole. Aluminium and magnesium hydroxide containing antacid reduces the absorption of Fexofenadine Hydrochloride.
    Pregnancy & lactationView
    US FDA pregnancy category of Fexofenadine Hydrochloride is C. So, Fexofenadine Hydrochloride should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    Overdose effectsView
    In case of an overdose, standard measures to remove any unabsorbed drug should be employed. Symptomatic and supportive treatment is recommended. There has been no reported case of an acute overdose of Fexofenadine hydrochloride.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    X-Din

    Fexofenadine Hydrochloride
    Tablet 180 mg Allopathic Non-sedating antihistamines

    Indications

    Urticaria

    Indication detailsView
    Fexofenadine Hydrochloride is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children. It is also indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria.
    Therapeutic classView
    Non-sedating antihistamines
    PharmacologyView
    Fexofenadine Hydrochloride is an antihistamine with selective peripheral H1-receptor antagonist activity. It is rapidly absorbed after oral administration and peak plasma concentration is reached in 2-3 hours. It does not appear to cross the blood brain barrier.
    DosageView
    Seasonal Allergic Rhinitis-

    Adults and children 12 years and older:
    • Tablet: 60 mg twice daily or 120 mg once daily or 180 mg once daily
    • In case of impaired renal function: 60 mg once daily
    Children from 6 to 11 years:
    • Tablet: 30 mg twice daily or 60 mg once daily
    • In case of impaired renal function: 30 mg once daily
    Children from 2 to 11 years
    • Suspension: 30 mg or 5 ml twice daily
    • In case of impaired renal function: 30 mg or 5 ml once daily


    Chronic Idiopathic Urticaria-

    Adults and children 12 years and older:
    • Tablet: 60 mg twice daily or 120 mg once daily or 180 mg once daily 
    • In case of impaired renal function: 60 mg once daily
    Children from 6 to 11 years:
    • Tablet: 30 mg twice daily or 60 mg once daily
    • In case of impaired renal function: 30 mg once daily
    Children from 6 months to less than 2 years:
    • Suspension: 15 mg or 2.5 ml (1/2 tsp) twice daily
    • In case of impaired renal function: 15 mg or 2.5 ml (1/2 tsp) once daily
    Children from 2 to 11 years:
    • Suspension: 30 mg or 5 ml (1 tsp) twice daily
    • In case of impaired renal function: 30 mg or 5 ml (1 tsp) once daily

    Side effectsView
    Common side effects are headache, fatigue, drowsiness, nausea, dry mouth and gastrointestinal disturbances.
    ContraindicationsView
    Contraindicated in patients with known hypersensitivity to Fexofenadine Hydrochloride or any of its ingredients.
    PrecautionsView
    Caution should be exercised in elderly patient and patient with decreased renal function.
    InteractionsView
    Plasma concentration of Fexofenadine Hydrochloride have been increased when given with erythromycin or ketoconazole. Aluminium and magnesium hydroxide containing antacid reduces the absorption of Fexofenadine Hydrochloride.
    Pregnancy & lactationView
    US FDA pregnancy category of Fexofenadine Hydrochloride is C. So, Fexofenadine Hydrochloride should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    Overdose effectsView
    In case of an overdose, standard measures to remove any unabsorbed drug should be employed. Symptomatic and supportive treatment is recommended. There has been no reported case of an acute overdose of Fexofenadine hydrochloride.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    X-Din

    Fexofenadine Hydrochloride
    Tablet 120 mg Allopathic Non-sedating antihistamines

    Indications

    Urticaria

    Indication detailsView
    Fexofenadine Hydrochloride is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children. It is also indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria.
    Therapeutic classView
    Non-sedating antihistamines
    PharmacologyView
    Fexofenadine Hydrochloride is an antihistamine with selective peripheral H1-receptor antagonist activity. It is rapidly absorbed after oral administration and peak plasma concentration is reached in 2-3 hours. It does not appear to cross the blood brain barrier.
    DosageView
    Seasonal Allergic Rhinitis-

    Adults and children 12 years and older:
    • Tablet: 60 mg twice daily or 120 mg once daily or 180 mg once daily
    • In case of impaired renal function: 60 mg once daily
    Children from 6 to 11 years:
    • Tablet: 30 mg twice daily or 60 mg once daily
    • In case of impaired renal function: 30 mg once daily
    Children from 2 to 11 years
    • Suspension: 30 mg or 5 ml twice daily
    • In case of impaired renal function: 30 mg or 5 ml once daily


    Chronic Idiopathic Urticaria-

    Adults and children 12 years and older:
    • Tablet: 60 mg twice daily or 120 mg once daily or 180 mg once daily 
    • In case of impaired renal function: 60 mg once daily
    Children from 6 to 11 years:
    • Tablet: 30 mg twice daily or 60 mg once daily
    • In case of impaired renal function: 30 mg once daily
    Children from 6 months to less than 2 years:
    • Suspension: 15 mg or 2.5 ml (1/2 tsp) twice daily
    • In case of impaired renal function: 15 mg or 2.5 ml (1/2 tsp) once daily
    Children from 2 to 11 years:
    • Suspension: 30 mg or 5 ml (1 tsp) twice daily
    • In case of impaired renal function: 30 mg or 5 ml (1 tsp) once daily

    Side effectsView
    Common side effects are headache, fatigue, drowsiness, nausea, dry mouth and gastrointestinal disturbances.
    ContraindicationsView
    Contraindicated in patients with known hypersensitivity to Fexofenadine Hydrochloride or any of its ingredients.
    PrecautionsView
    Caution should be exercised in elderly patient and patient with decreased renal function.
    InteractionsView
    Plasma concentration of Fexofenadine Hydrochloride have been increased when given with erythromycin or ketoconazole. Aluminium and magnesium hydroxide containing antacid reduces the absorption of Fexofenadine Hydrochloride.
    Pregnancy & lactationView
    US FDA pregnancy category of Fexofenadine Hydrochloride is C. So, Fexofenadine Hydrochloride should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    Overdose effectsView
    In case of an overdose, standard measures to remove any unabsorbed drug should be employed. Symptomatic and supportive treatment is recommended. There has been no reported case of an acute overdose of Fexofenadine hydrochloride.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    X-Jelly

    Hydroxyethyl Cellulose + Glycerin
    Topical Gel (1 gm + 1.3 gm)/50 gm Allopathic Miscellaneous topical agents

    Indications

    Lubrication

    Indication detailsView
    Helps lubricating in sexual intercourse specially for post menopausal women to reduce irritation, for lubrication during vaginal examinations, endoscopy, catheterization for gloves and instruments.
    Therapeutic classView
    Miscellaneous topical agents
    PharmacologyView
    Hydroxyethyl Cellulose and Glycerin are colorless, odorless, non-toxic viscous liquid. Both are used in medical, pharmaceutical and personal care preparations for improving smoothness & providing lubrication.
    DosageView
    Apply as required.
    ContraindicationsView
    Usually well-tolerated. People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it.
    PrecautionsView
    Only for external use. When using this product do not get into eyes.
    StorageView
    Store in a cool & dry place, protected from light. Keep out of reach of children.

    X-Pectoran

    Bromhexine Hydrochloride
    Tablet 8 mg Allopathic Cough expectorants & mucolytics

    Indications

    Bronchitis

    Indication detailsView
    Bromhexine is indicated in the treatment of respiratory tract disorders associated with productive cough. This include-
    • Tracheobronchitis
    • Bronchitis with emphysema
    • Bronchiectasis
    • Bronchitis with bronchospasm
    • Chronic inflammatory pulmonary conditions and
    • Pneumoconiosis.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Bromhexine Hydrochloride is an oral mucolytic agent. It disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces less viscous mucus, which makes easier the expectoration. It is rapidly & completely absorbed from the gastrointestinal tract. It is widely distributed into the body tissues.
    DosageView
    The recommended doses for adults and children are stated below:
    • Adult & Children over 12 years: 10 ml (2 teaspoons) 3 times daily
    • Children 6-12 years: 5 ml (1 teaspoon) 3 times daily
    • Children 2-6 years: 2.5 ml (1/2 teaspoon) 3 times daily
    • Bromhexine Hydrochloride is not recommended for children under 2 years of age without advice.
    Side effectsView
    Gastrointestinal side effects may occur occasionally. A transient rise in serum aminotransferase values has been reported. Other reported side effects include-headache, vertigo (dizziness) and allergic reactions.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Bromhexine Hydrochloride or any of the ingredients of this product.
    PrecautionsView
    Since mucolytics may disrupt the gastric mucosa bromhexine should be used with care in patients with a history of peptic ulcer disease. Care is also advisable in asthmatic patients. Clearance of bromhexine and its metabolites may be reduced in patients with severe hepatic or renal impairment.
    InteractionsView
    There are no known significant interactions with other drugs.
    Pregnancy & lactationView
    Use in Pregnancy: Special care is recommended during pregnancy. The benefits of bromhexine must be assessed against possible effects on children.

    Use in Lactation: Bromhexine is expected to enter breast milk. Therefore it is not recommended that bromhexine be taken by lactating mothers.
    StorageView
    Keep in a dry place away from light and heat. Keep out of reach of children.

    X-Pectoran

    Bromhexine Hydrochloride
    Syrup 4 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Bronchitis

    Indication detailsView
    Bromhexine is indicated in the treatment of respiratory tract disorders associated with productive cough. This include-
    • Tracheobronchitis
    • Bronchitis with emphysema
    • Bronchiectasis
    • Bronchitis with bronchospasm
    • Chronic inflammatory pulmonary conditions and
    • Pneumoconiosis.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Bromhexine Hydrochloride is an oral mucolytic agent. It disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces less viscous mucus, which makes easier the expectoration. It is rapidly & completely absorbed from the gastrointestinal tract. It is widely distributed into the body tissues.
    DosageView
    The recommended doses for adults and children are stated below:
    • Adult & Children over 12 years: 10 ml (2 teaspoons) 3 times daily
    • Children 6-12 years: 5 ml (1 teaspoon) 3 times daily
    • Children 2-6 years: 2.5 ml (1/2 teaspoon) 3 times daily
    • Bromhexine Hydrochloride is not recommended for children under 2 years of age without advice.
    Side effectsView
    Gastrointestinal side effects may occur occasionally. A transient rise in serum aminotransferase values has been reported. Other reported side effects include-headache, vertigo (dizziness) and allergic reactions.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Bromhexine Hydrochloride or any of the ingredients of this product.
    PrecautionsView
    Since mucolytics may disrupt the gastric mucosa bromhexine should be used with care in patients with a history of peptic ulcer disease. Care is also advisable in asthmatic patients. Clearance of bromhexine and its metabolites may be reduced in patients with severe hepatic or renal impairment.
    InteractionsView
    There are no known significant interactions with other drugs.
    Pregnancy & lactationView
    Use in Pregnancy: Special care is recommended during pregnancy. The benefits of bromhexine must be assessed against possible effects on children.

    Use in Lactation: Bromhexine is expected to enter breast milk. Therefore it is not recommended that bromhexine be taken by lactating mothers.
    StorageView
    Keep in a dry place away from light and heat. Keep out of reach of children.

    Xa Fast

    Aceclofenac
    Tablet 100 mg Allopathic Drugs for Osteoarthritis

    Indications

    Spondylitis

    Indication detailsView
    Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, toothache, trauma and lumbago.
    Therapeutic classView
    Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    PharmacologyView

    Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

    DosageView

    Extended release tablet: The recommended dose in adults is one 200 mg Aceclofenac tablet daily or as prescribed by the physician.
    Film coated tablet: The recommended dose in adults is 100 mg, twice daily.

    Side effectsView

    Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

    ContraindicationsView

    Aceclofenac is contraindicated in patients with known hypersensitivity to it or in whom aspirin or NSAIDs precipitate attacks of asthma.

    PrecautionsView

    Caution should be exercised to patients with active or suspected peptic ulcer or gastro-intestinal bleeding moderate to severe hepatic impairment and cardiac or renal impairment. Caution should also be exercised in patients suffering from dizziness or urticaria.

    InteractionsView
    No significant drug interactions has not been observed but close monitoring of patients is required when it is used with:
    • Lithium and Digoxin: may increase plasma concentration of lithium and digoxin.
    • Diuretics: may interact the activity of diuretics.
    • Anticoagulants: may enhance the activity of anticoagulant.
    • Methotrexate: may increase the plasma level of methotrexate.
    Pregnancy & lactationView

    The use of Aceclofenac should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.

    Pediatric usageView
    There are no clinical data on the use of Aceclofenac in children.
    StorageView

    keep in a dry place away from light and heat. Keep out of the reach of children.

    Xablin

    Pregabalin
    Capsule 50 mg Allopathic Adjunct anti-epileptic drugs
    Indication detailsView
    Pregabalin is indicated for:
    • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
    • Postherpetic neuralgia (PHN)
    • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
    • Fibromyalgia
    • Neuropathic pain associated with spinal cord injury
    Pregabalin CR tablet is indicated for:
    • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
    • Postherpetic neuralgia (PHN)
    Therapeutic classView
    Adjunct anti-epileptic drugs, Primary anti-epileptic drugs
    PharmacologyView
    Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It does not bind directly to GABAA, GABAB or benzodiazepine receptors. Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of Pregabalin has not been fully elucidated, results in animal studies suggest that binding to the alpha2-delta subunit may be involved in Pregabalin's anti-nociceptive and antiseizure effects.
    DosageView
    Neuropathic pain associated with diabetic peripheral neuropathy in adults (DPN): The maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Begin dosing of Pregabalin CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. The maximum recommended dose of Pregabalin CR capsule is 330 mg once daily.

    Postherpetic neuralgia in adults (PHN): The recommended dose of Pregabalin is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Pregabalin, may be treated with up to 300 mg two times a day or 200 mg three times a day (600 mg/day).

    Begin dosing of Pregabalin CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 330 mg once daily and who are able to tolerate Pregabalin CR capsule, may be treated with up to 660 mg once daily. In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, dosing above 330 mg/day should be reserved only for those patients who have on-going pain and are tolerating 330 mg daily. The maximum recommended dose of Pregabalin CR capsule is 660 mg once daily.

    Management of fibromyalgia in adults: The recommended dose of Pregabalin is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).

    Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Pregabalin is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate Pregabalin may be treated with up to 300 mg two times a day.

    Conversion from Pregabalin capsules to Pregabalin CR capsule tablet: When switching from Pregabalin capsules to Pregabalin CR capsule tablet on the day of the switch, instruct patients to take their morning dose of Pregabalin capsule as prescribed and initiate Pregabalin CR capsule therapy after an evening meal.

    Pregabalin tablet total daily dose (dosed 2 or 3 times daily): Pregabalin CR capsule capsule dose (dosed once a day)
    • 75 mg/daily: 82.5 mg/day
    • 150 mg/daily: 165 mg/day
    • 225 mg/daily: 247.5 mg/day
    • 300 mg/daily: 330 mg/day
    • 450 mg/daily: 495 mg/day
    • 600 mg/daily: 660 mg/day
    AdministrationView
    Route of administration: Pregabalin is taken in oral route. It can be taken with or without food. Pregabalin CR tablet should be administered after an evening meal. It should be swallowed whole and should not be split, crushed or chewed. If patients miss taking their dose of Pregabalin CR after an evening meal, then they should take their usual dose of Pregabalin CR prior to bedtime following a snack. If they miss taking the dose of Pregabalin CR prior to bedtime, then they should take their usual dose of Pregabalin CR following a morning meal. If they miss taking the dose of Pregabalin CR following the morning meal, then they should take their usual dose of Pregabalin CR at the usual time that evening following an evening meal. When discontinuing both Pregabalin and Pregabalin CR, it should be gradually tapered over a minimum of 1 week.
    Side effectsView
    Most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). Most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite.
    ContraindicationsView
    Pregabalin is contraindicated in patients with known hypersensitivity to Pregabalin or any of its components.
    PrecautionsView
    Angioedema (e.g., swelling of the throat, head and neck) can occur and may be associated with life threatening respiratory compromise requiring emergency treatment. Pregabalin should be discontinued immediately in these cases. Pregabalin should also be discontinued immediately if hypersensitivity reactions (e.g., hives, dyspnea and wheezing) occur. Antiepileptic drugs, including pregabalin, increase the risk of suicidal thoughts or behavior. Respiratory depression may occur with pregabalin when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Patients need to be monitored and dosage adjusted as appropriate. Pregabalin may cause dizziness and somnolence and impair patients ability to drive or operate machinery. Increased seizure frequency or other adverse reactions may occur if pregabalin is rapidly discontinued. Pregabalin should be withdrawn gradually over a minimum of 1 week. Pregabalin may cause peripheral edema. Caution should be exercised when coadministering pregabalin and thiazolidinedione antidiabetic agents.
    InteractionsView
    Pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions.
    Pregnancy & lactationView
    There are no adequate and well-controlled studies with pregabalin in pregnant women. Pregnant women should be advised of the potential risk to a fetus. Small amounts of pregabalin have been detected in the milk of lactating women. Because of the potential risk of tumorigenicity, breastfeeding is not recommended during treatment with pregabalin.
    Pediatric usageView
    Use in children and adolescents: Safety and effectiveness in pediatric patients have not been established for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain associated with spinal cord injury and fibromyalgia. In case of adjunctive therapy for partial onset seizures, safety and effectiveness in pediatric patients below the age of 1 month have not been established. The safety and effectiveness of pregabalin extended-release tablet in pediatric patients have not been established.
    Overdose effectsView
    In case of overdose with pregabalin, sign and symptoms are reduced consciousness, depression/anxiety, confusional state, agitation and restlessness. Seizures and heart block have also been reported. There is no specific antidote. If indicated, elimination of unabsorbed drug may be attempted by emesis or gastric lavage; usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient.
    StorageView
    Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

    Xablin

    Pregabalin
    Capsule 75 mg Allopathic Adjunct anti-epileptic drugs
    Indication detailsView
    Pregabalin is indicated for:
    • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
    • Postherpetic neuralgia (PHN)
    • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
    • Fibromyalgia
    • Neuropathic pain associated with spinal cord injury
    Pregabalin CR tablet is indicated for:
    • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
    • Postherpetic neuralgia (PHN)
    Therapeutic classView
    Adjunct anti-epileptic drugs, Primary anti-epileptic drugs
    PharmacologyView
    Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It does not bind directly to GABAA, GABAB or benzodiazepine receptors. Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of Pregabalin has not been fully elucidated, results in animal studies suggest that binding to the alpha2-delta subunit may be involved in Pregabalin's anti-nociceptive and antiseizure effects.
    DosageView
    Neuropathic pain associated with diabetic peripheral neuropathy in adults (DPN): The maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Begin dosing of Pregabalin CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. The maximum recommended dose of Pregabalin CR capsule is 330 mg once daily.

    Postherpetic neuralgia in adults (PHN): The recommended dose of Pregabalin is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Pregabalin, may be treated with up to 300 mg two times a day or 200 mg three times a day (600 mg/day).

    Begin dosing of Pregabalin CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 330 mg once daily and who are able to tolerate Pregabalin CR capsule, may be treated with up to 660 mg once daily. In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, dosing above 330 mg/day should be reserved only for those patients who have on-going pain and are tolerating 330 mg daily. The maximum recommended dose of Pregabalin CR capsule is 660 mg once daily.

    Management of fibromyalgia in adults: The recommended dose of Pregabalin is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).

    Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Pregabalin is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate Pregabalin may be treated with up to 300 mg two times a day.

    Conversion from Pregabalin capsules to Pregabalin CR capsule tablet: When switching from Pregabalin capsules to Pregabalin CR capsule tablet on the day of the switch, instruct patients to take their morning dose of Pregabalin capsule as prescribed and initiate Pregabalin CR capsule therapy after an evening meal.

    Pregabalin tablet total daily dose (dosed 2 or 3 times daily): Pregabalin CR capsule capsule dose (dosed once a day)
    • 75 mg/daily: 82.5 mg/day
    • 150 mg/daily: 165 mg/day
    • 225 mg/daily: 247.5 mg/day
    • 300 mg/daily: 330 mg/day
    • 450 mg/daily: 495 mg/day
    • 600 mg/daily: 660 mg/day
    AdministrationView
    Route of administration: Pregabalin is taken in oral route. It can be taken with or without food. Pregabalin CR tablet should be administered after an evening meal. It should be swallowed whole and should not be split, crushed or chewed. If patients miss taking their dose of Pregabalin CR after an evening meal, then they should take their usual dose of Pregabalin CR prior to bedtime following a snack. If they miss taking the dose of Pregabalin CR prior to bedtime, then they should take their usual dose of Pregabalin CR following a morning meal. If they miss taking the dose of Pregabalin CR following the morning meal, then they should take their usual dose of Pregabalin CR at the usual time that evening following an evening meal. When discontinuing both Pregabalin and Pregabalin CR, it should be gradually tapered over a minimum of 1 week.
    Side effectsView
    Most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). Most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite.
    ContraindicationsView
    Pregabalin is contraindicated in patients with known hypersensitivity to Pregabalin or any of its components.
    PrecautionsView
    Angioedema (e.g., swelling of the throat, head and neck) can occur and may be associated with life threatening respiratory compromise requiring emergency treatment. Pregabalin should be discontinued immediately in these cases. Pregabalin should also be discontinued immediately if hypersensitivity reactions (e.g., hives, dyspnea and wheezing) occur. Antiepileptic drugs, including pregabalin, increase the risk of suicidal thoughts or behavior. Respiratory depression may occur with pregabalin when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Patients need to be monitored and dosage adjusted as appropriate. Pregabalin may cause dizziness and somnolence and impair patients ability to drive or operate machinery. Increased seizure frequency or other adverse reactions may occur if pregabalin is rapidly discontinued. Pregabalin should be withdrawn gradually over a minimum of 1 week. Pregabalin may cause peripheral edema. Caution should be exercised when coadministering pregabalin and thiazolidinedione antidiabetic agents.
    InteractionsView
    Pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions.
    Pregnancy & lactationView
    There are no adequate and well-controlled studies with pregabalin in pregnant women. Pregnant women should be advised of the potential risk to a fetus. Small amounts of pregabalin have been detected in the milk of lactating women. Because of the potential risk of tumorigenicity, breastfeeding is not recommended during treatment with pregabalin.
    Pediatric usageView
    Use in children and adolescents: Safety and effectiveness in pediatric patients have not been established for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain associated with spinal cord injury and fibromyalgia. In case of adjunctive therapy for partial onset seizures, safety and effectiveness in pediatric patients below the age of 1 month have not been established. The safety and effectiveness of pregabalin extended-release tablet in pediatric patients have not been established.
    Overdose effectsView
    In case of overdose with pregabalin, sign and symptoms are reduced consciousness, depression/anxiety, confusional state, agitation and restlessness. Seizures and heart block have also been reported. There is no specific antidote. If indicated, elimination of unabsorbed drug may be attempted by emesis or gastric lavage; usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient.
    StorageView
    Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

    Xalacom

    Latanoprost + Timolol
    Ophthalmic Solution 0.005%+0.5% Allopathic Drugs for miotics and glaucoma

    Indications

    Open angle glaucoma

    Indication detailsView
    This preparation is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufftciently responsive to β-blockers, prostaglandins or other IOP lowering agents.
    Therapeutic classView
    Drugs for miotics and glaucoma
    PharmacologyView
    Latanoprost is an analogue of prostaglandin F2α, it reduces intraocular pressure (IOP) by increasing outflow of aqueous humour.

    Timolol is a non-selective adrenergic blocker. It lowers IOP by decreasing the formation of aqueous by the ciliary epithelium.
    DosageView
    Adult or elderly: The recommended adult (including the elderly) dosage of is one drop in the affected eye(s) once daily. If one dose is missed, treatment should continue with the next dose as normal.

    Children: Safety and effectiveness in children has not been established. This is therefore is not recommended for use in children.
    Side effectsView
    This combination is generally well tolerated. The most frequent findings of increased iris pigmentation were in patients with green-brown, yellow-brown and blue/grey/brown irides. In patients with homogeneously blue, grey, green or brown eyes, the change was only rarely seen. Darkening, thickening and lengthening of the eye lashes have been reported. The most frequently reported undesirable effects in clinical trials were irritation of the eye, including stinging, burning and ,itching, eye hyperaemia, corneal disorders, coniunctivitis blepharitis, eye pain, headache and skin rash.
    ContraindicationsView
    This combination is contraindicated in patients with Known hypersensitivity to Latanoprost, Timolol and benzalkonium chloride or any other ingredient in the product. This combination is also contraindicated for the following conditions such as reactive airway disease including bronchial asthma, history of bronchial asthma or severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
    PrecautionsView
    This preparation should be used with caution in patients with macular edema, aphakic patients, pseudophakic parients with a torn posterior lens capsule or in patients with known risk factors for macular edema.It should be administered with caution in patients subjected to spontaneous hypoglycaemia or to diabetic patients who are receiving insulin or oral hypoglycaemic agents.Caution should also be exercised to patients wearing contact lenses or drive and use machines.
    InteractionsView
    No specific interaction studies have been performed with this preparation. Patients who are receiving treatment with this preparation and an oral β-adrenergic blocking agent should be observed for potential additive effects of β-blockade, both systemic and on lntraocular pressure The concomitant use of two topical β-adrenergic blocking agents is not recommended. Although this preparation alone has little or no effect on pupil size, mydriasis has occasionally been reported when Timolol is given with epinephrine. β-blockers may increase the hypoglycemic effect of antidiabetic agents. In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with Benzalkonium chloride, the preservative used in this preparatlon. If such drugs are used they should be administered with an interval of at least 5 minutes between applications. Similarly, several contact lens soakinq solutions contain thimerosal.
    Pregnancy & lactationView
    No reproduction toxicity studies have been conducted with this combination.This combination should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Latanoprost and its metabolites may pass into breast milk. Timolol maleate has been detected in human milk following ocular administration. Because of the potential serious adverse reactions in nursing infants, this preparation should be used with caution in nursing women.
    Overdose effectsView
    There is no human data available on over dosage with this preparation.Symptoms of systemic Timolol over dosage are bradycardia, hypotenslon, bronchospasm, and cardiac arrest. If such symptoms occur,treatment should be symptomatic and supportive. The ocular effects of Latanoprost administered at high doses are not known. If overdose with this preparation occurs, treatment should be symptomatic.
    StorageView
    Store at 2-8° C. For opened bottles, may store below 25° C.

    Xalanol

    Latanoprost + Timolol
    Ophthalmic Solution 0.005%+0.5% Allopathic Drugs for miotics and glaucoma

    Indications

    Open angle glaucoma

    Indication detailsView
    This preparation is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufftciently responsive to β-blockers, prostaglandins or other IOP lowering agents.
    Therapeutic classView
    Drugs for miotics and glaucoma
    PharmacologyView
    Latanoprost is an analogue of prostaglandin F2α, it reduces intraocular pressure (IOP) by increasing outflow of aqueous humour.

    Timolol is a non-selective adrenergic blocker. It lowers IOP by decreasing the formation of aqueous by the ciliary epithelium.
    DosageView
    Adult or elderly: The recommended adult (including the elderly) dosage of is one drop in the affected eye(s) once daily. If one dose is missed, treatment should continue with the next dose as normal.

    Children: Safety and effectiveness in children has not been established. This is therefore is not recommended for use in children.
    Side effectsView
    This combination is generally well tolerated. The most frequent findings of increased iris pigmentation were in patients with green-brown, yellow-brown and blue/grey/brown irides. In patients with homogeneously blue, grey, green or brown eyes, the change was only rarely seen. Darkening, thickening and lengthening of the eye lashes have been reported. The most frequently reported undesirable effects in clinical trials were irritation of the eye, including stinging, burning and ,itching, eye hyperaemia, corneal disorders, coniunctivitis blepharitis, eye pain, headache and skin rash.
    ContraindicationsView
    This combination is contraindicated in patients with Known hypersensitivity to Latanoprost, Timolol and benzalkonium chloride or any other ingredient in the product. This combination is also contraindicated for the following conditions such as reactive airway disease including bronchial asthma, history of bronchial asthma or severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
    PrecautionsView
    This preparation should be used with caution in patients with macular edema, aphakic patients, pseudophakic parients with a torn posterior lens capsule or in patients with known risk factors for macular edema.It should be administered with caution in patients subjected to spontaneous hypoglycaemia or to diabetic patients who are receiving insulin or oral hypoglycaemic agents.Caution should also be exercised to patients wearing contact lenses or drive and use machines.
    InteractionsView
    No specific interaction studies have been performed with this preparation. Patients who are receiving treatment with this preparation and an oral β-adrenergic blocking agent should be observed for potential additive effects of β-blockade, both systemic and on lntraocular pressure The concomitant use of two topical β-adrenergic blocking agents is not recommended. Although this preparation alone has little or no effect on pupil size, mydriasis has occasionally been reported when Timolol is given with epinephrine. β-blockers may increase the hypoglycemic effect of antidiabetic agents. In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with Benzalkonium chloride, the preservative used in this preparatlon. If such drugs are used they should be administered with an interval of at least 5 minutes between applications. Similarly, several contact lens soakinq solutions contain thimerosal.
    Pregnancy & lactationView
    No reproduction toxicity studies have been conducted with this combination.This combination should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Latanoprost and its metabolites may pass into breast milk. Timolol maleate has been detected in human milk following ocular administration. Because of the potential serious adverse reactions in nursing infants, this preparation should be used with caution in nursing women.
    Overdose effectsView
    There is no human data available on over dosage with this preparation.Symptoms of systemic Timolol over dosage are bradycardia, hypotenslon, bronchospasm, and cardiac arrest. If such symptoms occur,treatment should be symptomatic and supportive. The ocular effects of Latanoprost administered at high doses are not known. If overdose with this preparation occurs, treatment should be symptomatic.
    StorageView
    Store at 2-8° C. For opened bottles, may store below 25° C.

    Xalaprost

    Latanoprost
    Ophthalmic Solution 0.01% Allopathic Drugs for miotics and glaucoma

    Indications

    Open angle glaucoma

    Indication detailsView
    Latanoprost Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
    Therapeutic classView
    Drugs for miotics and glaucoma
    PharmacologyView
    Latanoprost is an analogue of prostaglandin F2α. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
    DosageView
    The recommended dosage is 1 drop (1.5 mcg) in the affected eye(s) once daily in the evening. This is for topical ophthalmic use only. Not for injection or oral use.
    Side effectsView
    Eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema, including cystoid macular edema. The ocular adverse events and ocular signs and symptoms reported in 5- 15% of the patients on latanoprost in the 6 month, multicenter, double-masked, active-controlled trials were blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy. Local conjunctiva hyperemia was observed; however, less than 1% of the latanoprost treated patients required discontinuation of therapy because of intolerance to conjunctival hyperemia.
    ContraindicationsView
    Known hypersensitivity to latanoprost, benzalkonium chloride or any other ingredients in this product.
    PrecautionsView
    Ophthalmic Solution may gradually increase the pigmentation of the iris. The eye color change is due to increased melanin content in the stromal melanocytes of the iris rather than to an increase in the number of melanocytes. During clinical trials, the increase in brown iris pigment has not been shown to progress further upon discontinuation of treatment, but the resultant color change may be permanent. Eyelid skin darkening, which may be reversible. There may be increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment. It should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation. This drug should be used with caution in patients who do not have an intact posterior capsule or who have known risk factors for macular edema.
    InteractionsView
    In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost. If such drugs are used they should be administered with an interval of at least 5 minutes between applications.
    Pregnancy & lactationView
    Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
    Pediatric usageView
    Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

    Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
    StorageView
    Before opening the cap, keep the bottle in its box in a refrigerator (2°-8° C) protected from light. After opening, keep the bottle in its box in a cool place below 25° C. The contents should be used within one month after the dropper is opened. Keep out of reach of children

    Xalatan

    Latanoprost
    Ophthalmic Solution 0.01% Allopathic Drugs for miotics and glaucoma

    Indications

    Open angle glaucoma

    Indication detailsView
    Latanoprost Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
    Therapeutic classView
    Drugs for miotics and glaucoma
    PharmacologyView
    Latanoprost is an analogue of prostaglandin F2α. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
    DosageView
    The recommended dosage is 1 drop (1.5 mcg) in the affected eye(s) once daily in the evening. This is for topical ophthalmic use only. Not for injection or oral use.
    Side effectsView
    Eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema, including cystoid macular edema. The ocular adverse events and ocular signs and symptoms reported in 5- 15% of the patients on latanoprost in the 6 month, multicenter, double-masked, active-controlled trials were blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy. Local conjunctiva hyperemia was observed; however, less than 1% of the latanoprost treated patients required discontinuation of therapy because of intolerance to conjunctival hyperemia.
    ContraindicationsView
    Known hypersensitivity to latanoprost, benzalkonium chloride or any other ingredients in this product.
    PrecautionsView
    Ophthalmic Solution may gradually increase the pigmentation of the iris. The eye color change is due to increased melanin content in the stromal melanocytes of the iris rather than to an increase in the number of melanocytes. During clinical trials, the increase in brown iris pigment has not been shown to progress further upon discontinuation of treatment, but the resultant color change may be permanent. Eyelid skin darkening, which may be reversible. There may be increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment. It should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation. This drug should be used with caution in patients who do not have an intact posterior capsule or who have known risk factors for macular edema.
    InteractionsView
    In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost. If such drugs are used they should be administered with an interval of at least 5 minutes between applications.
    Pregnancy & lactationView
    Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
    Pediatric usageView
    Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

    Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
    StorageView
    Before opening the cap, keep the bottle in its box in a refrigerator (2°-8° C) protected from light. After opening, keep the bottle in its box in a cool place below 25° C. The contents should be used within one month after the dropper is opened. Keep out of reach of children

    Xalcort

    Deflazacort
    Tablet 30 mg Allopathic Glucocorticoids

    Indications

    Allergic and inflammatory disorders

    Indication detailsView
    Deflazacort is indicated in-
    • Anaphylaxis, asthma, severe hypersensitivity reactions
    • Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica
    • Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, sarcoidosis
    • Pemphigus,bullous pemphigoid, pyoderma gangrenosum
    • Minimal change nephrotic syndrome, acute interstitial nephritis
    • Rheumatic carditis
    • Ulcerative colitis, Crohn's disease
    • Uveitis, optic neuritis
    • Autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura
    • Acute and lymphatic leukaemia, malignant lymphoma, multiple myeloma
    • Immune suppression in transplantation
    Therapeutic classView
    Glucocorticoids
    PharmacologyView
    Deflazacort provides anti-inflammatory action by inhibiting Phospholipase A2 enzyme which is responsible for prostaglandin synthesis. Besides Deflazacort decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Deflazacort provides immunosuppressive action.
    DosageView
    Adults-
    • For acute disorders: Up to 120 mg/day Deflazacort may need to be given initially. Maintenance doses in most conditions are within the range of 3-18 mg/day.
    • Rheumatoid arthritis: The maintenance dose is usually within the range of 3-18 mg/day. The smallest effective dose should be used and increased if necessary.
    • Bronchial asthma: In the treatment of an acute attack, high doses of 48-72 mg/day may be needed depending on severity and gradually reduced once the attack has been controlled. For maintenance in chronic asthma, doses should be titrated to the lowest dose that controls symptoms.
    • Other conditions: The dose of Deflazacort depends on clinical need titrated to the lowest effective dose for maintenance. Starting doses may be estimated on the basis of ratio of 5 mg prednisone or prednisolone to 6 mg.
    Children: There has been limited exposure of children to Deflazacort in clinical trials. In children, the indications for glucocorticoids arethe same as for adults, but it is important that the lowest effective dosage is used. Alternate day administration may be appropriate. Doses of Deflazacort usually lie in the range 0.25-1.5 mg/kg/day.

    The following ranges provide general guidance:
    • Juvenile chronic arthritis: The usual maintenance dose is between 0.25-1.0 mg/kg/day.
    • Nephrotic syndrome: Initial dose of usually 1.5 mg/kg/day followed by down titration according to clinical need.
    • Bronchial asthma: On the basis of the potency ratio, the initial dose should be between 0.25-1.0 mg/kg on alternate days.
    Deflazacort withdrawal: In patients who have received more than physiological doses of systemic corticosteroids (approximately 9 mg per day or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.
    Side effectsView
    GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent Ml, thromboembolism.
    ContraindicationsView
    Hypersensitivity to or any of the ingredients. Patients receiving live virus immunization.
    PrecautionsView
    The following clinical conditions require special caution and frequent patient monitoring is necessary-
    • Cardiac disease or congestive heart failure (except in the presence of active rheumatic carditis), hypertension, thromboembolic disorders. Glucocorticoids can cause salt and water retention and increased excretion of potassium. Dietary salt restriction and potassium supplementation may be necessary.
    • Gastritis or oesophagitis, diverticulitis, ulcerative colitis if there is the probability of impending perforation, abscess or pyogenic infections, fresh intestinal anastomosis, active or latent peptic ulcer.
    • Diabetes mellitus or family history, osteoporosis, myasthenia gravis, renal insufficiency.
    • Emotional instability or psychotic tendency, epilepsy.
    • Previous corticosteroid-induced myopathy.
    • Liver failure.
    • Hypothyroidism and cirrhosis, which may increase the glucocorticoid effect.
    • Ocular herpes simplex because of possible corneal perforation.
    InteractionsView
    Deflazacort is metabolized in the liver. It is recommended to increase the maintenance dose of Deflazacort if drugs which are liver enzyme inducers are co-administered, e.g. rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone and aminoglutethimide. For drugs which inhibit liver enzymes, (e.g. ketoconazole) it may be possible to reduce the maintenance dose of Deflazacort.
    Pregnancy & lactationView
    Pregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.

    Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression but the benefits of breastfeeding are likely to outweigh any theoretical risk.
    Pediatric usageView
    Hepatic Impairment: In patients with hepatic impairment, blood levels of may be increased. Therefore the dose of Deflazacort should be carefully monitored and adjusted to the minimum effective dose.

    Renal Impairment: In renally impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.

    Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary. The common adverse effects of systemic corticosteroids may be associated with more serious consequences in old age.
    StorageView
    Store in a cool (below 25°C) and dry place, protected from light & moisture. Keep out of the reach of children.

    Xalcort

    Deflazacort
    Tablet 24 mg Allopathic Glucocorticoids

    Indications

    Allergic and inflammatory disorders

    Indication detailsView
    Deflazacort is indicated in-
    • Anaphylaxis, asthma, severe hypersensitivity reactions
    • Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica
    • Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, sarcoidosis
    • Pemphigus,bullous pemphigoid, pyoderma gangrenosum
    • Minimal change nephrotic syndrome, acute interstitial nephritis
    • Rheumatic carditis
    • Ulcerative colitis, Crohn's disease
    • Uveitis, optic neuritis
    • Autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura
    • Acute and lymphatic leukaemia, malignant lymphoma, multiple myeloma
    • Immune suppression in transplantation
    Therapeutic classView
    Glucocorticoids
    PharmacologyView
    Deflazacort provides anti-inflammatory action by inhibiting Phospholipase A2 enzyme which is responsible for prostaglandin synthesis. Besides Deflazacort decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Deflazacort provides immunosuppressive action.
    DosageView
    Adults-
    • For acute disorders: Up to 120 mg/day Deflazacort may need to be given initially. Maintenance doses in most conditions are within the range of 3-18 mg/day.
    • Rheumatoid arthritis: The maintenance dose is usually within the range of 3-18 mg/day. The smallest effective dose should be used and increased if necessary.
    • Bronchial asthma: In the treatment of an acute attack, high doses of 48-72 mg/day may be needed depending on severity and gradually reduced once the attack has been controlled. For maintenance in chronic asthma, doses should be titrated to the lowest dose that controls symptoms.
    • Other conditions: The dose of Deflazacort depends on clinical need titrated to the lowest effective dose for maintenance. Starting doses may be estimated on the basis of ratio of 5 mg prednisone or prednisolone to 6 mg.
    Children: There has been limited exposure of children to Deflazacort in clinical trials. In children, the indications for glucocorticoids arethe same as for adults, but it is important that the lowest effective dosage is used. Alternate day administration may be appropriate. Doses of Deflazacort usually lie in the range 0.25-1.5 mg/kg/day.

    The following ranges provide general guidance:
    • Juvenile chronic arthritis: The usual maintenance dose is between 0.25-1.0 mg/kg/day.
    • Nephrotic syndrome: Initial dose of usually 1.5 mg/kg/day followed by down titration according to clinical need.
    • Bronchial asthma: On the basis of the potency ratio, the initial dose should be between 0.25-1.0 mg/kg on alternate days.
    Deflazacort withdrawal: In patients who have received more than physiological doses of systemic corticosteroids (approximately 9 mg per day or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.
    Side effectsView
    GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent Ml, thromboembolism.
    ContraindicationsView
    Hypersensitivity to or any of the ingredients. Patients receiving live virus immunization.
    PrecautionsView
    The following clinical conditions require special caution and frequent patient monitoring is necessary-
    • Cardiac disease or congestive heart failure (except in the presence of active rheumatic carditis), hypertension, thromboembolic disorders. Glucocorticoids can cause salt and water retention and increased excretion of potassium. Dietary salt restriction and potassium supplementation may be necessary.
    • Gastritis or oesophagitis, diverticulitis, ulcerative colitis if there is the probability of impending perforation, abscess or pyogenic infections, fresh intestinal anastomosis, active or latent peptic ulcer.
    • Diabetes mellitus or family history, osteoporosis, myasthenia gravis, renal insufficiency.
    • Emotional instability or psychotic tendency, epilepsy.
    • Previous corticosteroid-induced myopathy.
    • Liver failure.
    • Hypothyroidism and cirrhosis, which may increase the glucocorticoid effect.
    • Ocular herpes simplex because of possible corneal perforation.
    InteractionsView
    Deflazacort is metabolized in the liver. It is recommended to increase the maintenance dose of Deflazacort if drugs which are liver enzyme inducers are co-administered, e.g. rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone and aminoglutethimide. For drugs which inhibit liver enzymes, (e.g. ketoconazole) it may be possible to reduce the maintenance dose of Deflazacort.
    Pregnancy & lactationView
    Pregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.

    Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression but the benefits of breastfeeding are likely to outweigh any theoretical risk.
    Pediatric usageView
    Hepatic Impairment: In patients with hepatic impairment, blood levels of may be increased. Therefore the dose of Deflazacort should be carefully monitored and adjusted to the minimum effective dose.

    Renal Impairment: In renally impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.

    Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary. The common adverse effects of systemic corticosteroids may be associated with more serious consequences in old age.
    StorageView
    Store in a cool (below 25°C) and dry place, protected from light & moisture. Keep out of the reach of children.

    Xalcort

    Deflazacort
    Oral Suspension 6 mg/5 ml Allopathic Glucocorticoids

    Indications

    Allergic and inflammatory disorders

    Indication detailsView
    Deflazacort is indicated in-
    • Anaphylaxis, asthma, severe hypersensitivity reactions
    • Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica
    • Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, sarcoidosis
    • Pemphigus,bullous pemphigoid, pyoderma gangrenosum
    • Minimal change nephrotic syndrome, acute interstitial nephritis
    • Rheumatic carditis
    • Ulcerative colitis, Crohn's disease
    • Uveitis, optic neuritis
    • Autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura
    • Acute and lymphatic leukaemia, malignant lymphoma, multiple myeloma
    • Immune suppression in transplantation
    Therapeutic classView
    Glucocorticoids
    PharmacologyView
    Deflazacort provides anti-inflammatory action by inhibiting Phospholipase A2 enzyme which is responsible for prostaglandin synthesis. Besides Deflazacort decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Deflazacort provides immunosuppressive action.
    DosageView
    Adults-
    • For acute disorders: Up to 120 mg/day Deflazacort may need to be given initially. Maintenance doses in most conditions are within the range of 3-18 mg/day.
    • Rheumatoid arthritis: The maintenance dose is usually within the range of 3-18 mg/day. The smallest effective dose should be used and increased if necessary.
    • Bronchial asthma: In the treatment of an acute attack, high doses of 48-72 mg/day may be needed depending on severity and gradually reduced once the attack has been controlled. For maintenance in chronic asthma, doses should be titrated to the lowest dose that controls symptoms.
    • Other conditions: The dose of Deflazacort depends on clinical need titrated to the lowest effective dose for maintenance. Starting doses may be estimated on the basis of ratio of 5 mg prednisone or prednisolone to 6 mg.
    Children: There has been limited exposure of children to Deflazacort in clinical trials. In children, the indications for glucocorticoids arethe same as for adults, but it is important that the lowest effective dosage is used. Alternate day administration may be appropriate. Doses of Deflazacort usually lie in the range 0.25-1.5 mg/kg/day.

    The following ranges provide general guidance:
    • Juvenile chronic arthritis: The usual maintenance dose is between 0.25-1.0 mg/kg/day.
    • Nephrotic syndrome: Initial dose of usually 1.5 mg/kg/day followed by down titration according to clinical need.
    • Bronchial asthma: On the basis of the potency ratio, the initial dose should be between 0.25-1.0 mg/kg on alternate days.
    Deflazacort withdrawal: In patients who have received more than physiological doses of systemic corticosteroids (approximately 9 mg per day or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.
    Side effectsView
    GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent Ml, thromboembolism.
    ContraindicationsView
    Hypersensitivity to or any of the ingredients. Patients receiving live virus immunization.
    PrecautionsView
    The following clinical conditions require special caution and frequent patient monitoring is necessary-
    • Cardiac disease or congestive heart failure (except in the presence of active rheumatic carditis), hypertension, thromboembolic disorders. Glucocorticoids can cause salt and water retention and increased excretion of potassium. Dietary salt restriction and potassium supplementation may be necessary.
    • Gastritis or oesophagitis, diverticulitis, ulcerative colitis if there is the probability of impending perforation, abscess or pyogenic infections, fresh intestinal anastomosis, active or latent peptic ulcer.
    • Diabetes mellitus or family history, osteoporosis, myasthenia gravis, renal insufficiency.
    • Emotional instability or psychotic tendency, epilepsy.
    • Previous corticosteroid-induced myopathy.
    • Liver failure.
    • Hypothyroidism and cirrhosis, which may increase the glucocorticoid effect.
    • Ocular herpes simplex because of possible corneal perforation.
    InteractionsView
    Deflazacort is metabolized in the liver. It is recommended to increase the maintenance dose of Deflazacort if drugs which are liver enzyme inducers are co-administered, e.g. rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone and aminoglutethimide. For drugs which inhibit liver enzymes, (e.g. ketoconazole) it may be possible to reduce the maintenance dose of Deflazacort.
    Pregnancy & lactationView
    Pregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.

    Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression but the benefits of breastfeeding are likely to outweigh any theoretical risk.
    Pediatric usageView
    Hepatic Impairment: In patients with hepatic impairment, blood levels of may be increased. Therefore the dose of Deflazacort should be carefully monitored and adjusted to the minimum effective dose.

    Renal Impairment: In renally impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.

    Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary. The common adverse effects of systemic corticosteroids may be associated with more serious consequences in old age.
    StorageView
    Store in a cool (below 25°C) and dry place, protected from light & moisture. Keep out of the reach of children.

    Xalcort

    Deflazacort
    Tablet 6 mg Allopathic Glucocorticoids

    Indications

    Allergic and inflammatory disorders

    Indication detailsView
    Deflazacort is indicated in-
    • Anaphylaxis, asthma, severe hypersensitivity reactions
    • Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica
    • Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, sarcoidosis
    • Pemphigus,bullous pemphigoid, pyoderma gangrenosum
    • Minimal change nephrotic syndrome, acute interstitial nephritis
    • Rheumatic carditis
    • Ulcerative colitis, Crohn's disease
    • Uveitis, optic neuritis
    • Autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura
    • Acute and lymphatic leukaemia, malignant lymphoma, multiple myeloma
    • Immune suppression in transplantation
    Therapeutic classView
    Glucocorticoids
    PharmacologyView
    Deflazacort provides anti-inflammatory action by inhibiting Phospholipase A2 enzyme which is responsible for prostaglandin synthesis. Besides Deflazacort decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Deflazacort provides immunosuppressive action.
    DosageView
    Adults-
    • For acute disorders: Up to 120 mg/day Deflazacort may need to be given initially. Maintenance doses in most conditions are within the range of 3-18 mg/day.
    • Rheumatoid arthritis: The maintenance dose is usually within the range of 3-18 mg/day. The smallest effective dose should be used and increased if necessary.
    • Bronchial asthma: In the treatment of an acute attack, high doses of 48-72 mg/day may be needed depending on severity and gradually reduced once the attack has been controlled. For maintenance in chronic asthma, doses should be titrated to the lowest dose that controls symptoms.
    • Other conditions: The dose of Deflazacort depends on clinical need titrated to the lowest effective dose for maintenance. Starting doses may be estimated on the basis of ratio of 5 mg prednisone or prednisolone to 6 mg.
    Children: There has been limited exposure of children to Deflazacort in clinical trials. In children, the indications for glucocorticoids arethe same as for adults, but it is important that the lowest effective dosage is used. Alternate day administration may be appropriate. Doses of Deflazacort usually lie in the range 0.25-1.5 mg/kg/day.

    The following ranges provide general guidance:
    • Juvenile chronic arthritis: The usual maintenance dose is between 0.25-1.0 mg/kg/day.
    • Nephrotic syndrome: Initial dose of usually 1.5 mg/kg/day followed by down titration according to clinical need.
    • Bronchial asthma: On the basis of the potency ratio, the initial dose should be between 0.25-1.0 mg/kg on alternate days.
    Deflazacort withdrawal: In patients who have received more than physiological doses of systemic corticosteroids (approximately 9 mg per day or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.
    Side effectsView
    GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent Ml, thromboembolism.
    ContraindicationsView
    Hypersensitivity to or any of the ingredients. Patients receiving live virus immunization.
    PrecautionsView
    The following clinical conditions require special caution and frequent patient monitoring is necessary-
    • Cardiac disease or congestive heart failure (except in the presence of active rheumatic carditis), hypertension, thromboembolic disorders. Glucocorticoids can cause salt and water retention and increased excretion of potassium. Dietary salt restriction and potassium supplementation may be necessary.
    • Gastritis or oesophagitis, diverticulitis, ulcerative colitis if there is the probability of impending perforation, abscess or pyogenic infections, fresh intestinal anastomosis, active or latent peptic ulcer.
    • Diabetes mellitus or family history, osteoporosis, myasthenia gravis, renal insufficiency.
    • Emotional instability or psychotic tendency, epilepsy.
    • Previous corticosteroid-induced myopathy.
    • Liver failure.
    • Hypothyroidism and cirrhosis, which may increase the glucocorticoid effect.
    • Ocular herpes simplex because of possible corneal perforation.
    InteractionsView
    Deflazacort is metabolized in the liver. It is recommended to increase the maintenance dose of Deflazacort if drugs which are liver enzyme inducers are co-administered, e.g. rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone and aminoglutethimide. For drugs which inhibit liver enzymes, (e.g. ketoconazole) it may be possible to reduce the maintenance dose of Deflazacort.
    Pregnancy & lactationView
    Pregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.

    Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression but the benefits of breastfeeding are likely to outweigh any theoretical risk.
    Pediatric usageView
    Hepatic Impairment: In patients with hepatic impairment, blood levels of may be increased. Therefore the dose of Deflazacort should be carefully monitored and adjusted to the minimum effective dose.

    Renal Impairment: In renally impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.

    Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary. The common adverse effects of systemic corticosteroids may be associated with more serious consequences in old age.
    StorageView
    Store in a cool (below 25°C) and dry place, protected from light & moisture. Keep out of the reach of children.